Results 21 to 30 of about 286,478 (209)
Journal of Pharmacological Sciences, 2009 This study examined the effect of ozagrel, a thromboxane A2 synthase inhibitor, on the accumulation of leucocytes and chemokine mRNA expression in lungs experimentally injured using oleic acid (OA).
Yoichi Ishitsuka +8 more
doaj +1 more source
A Pilot Study on the Effect of Angiotensin Receptor Blockers on Platelet Aggregation in Hypertensive Patients- A Prospective Observational Study [PDF]
Journal of Clinical and Diagnostic Research, 2016 Introduction: Thrombosis is an invariable component contributing to cardiovascular events in patients with hypertension. One of the risk factors of cardiovascular disease is increased platelet activity.
Arun Suresh +6 more
doaj +1 more source
Possible mechanism of action of Mentha Arvensis in cardiovascular diseases
International Journal of Endorsing Health Science Research, 2014 Mentha arvensis (MA) is traditionally used in hypertension and in patients with ischemic heart disease. The scientific rationale for its use is not known.
Saima Gul, Humaira Gul, Rukhsana Nawaz
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020 Background Antiplatelet therapy with aspirin (acetylsalicylic acid [ASA]) is less efficient in some coronary patients, which increases their risk of developing thrombosis. Elevated blood levels of thromboinflammatory mediators, like soluble CD40L (sCD40L)
Kevin Kojok +4 more
doaj +1 more source
Expression of Thromboxane A2 Receptor Gene and Thromboxane A2 Synthase in Bovine Corpora Lutea [PDF]
Biology of Reproduction, 1992 Studies were undertaken to investigate the expression of thromboxane (TXA2) receptor gene, from mRNA to functional receptor protein in terms of ligand binding, along with the cellular and subcellular distribution of the enzyme that catalyzes the formation of the ligand for the receptors.
Z M, Lei, C V, Rao, C, Chakraborty
openaire +2 more sources
Arterial thromboxane A2-induced transient contraction after IL-1β exposure
European Journal of Inflammation, 2022 The involvement of thromboxane A2 (TXA2) in systemic inflammation and infection is well recognized. However, there are few reports on the involvement of prostanoids in warm shock (the initial pathology of sepsis). Previous studies showed that interleukin
Katsuya Yuui, Risa Kudo, Shogo Kasuda
doaj +1 more source
Journal of Ginseng Research, 2019 Background: Thromboxane A2 (TXA2) induces platelet aggregation and promotes thrombus formation. Although ginsenoside Ro (G-Ro) from Panax ginseng is known to exhibit a Ca2+-antagonistic antiplatelet effect, whether it inhibits Ca2+-dependent cytosolic ...
Jung-Hae Shin +3 more
doaj +1 more source
Folia Medica Indonesiana, 2018 Endothelial dysfunction and vascular injuries are the early processes in thrombogenesis leading to thrombotic stroke. These processes trigger platelet activation characterized by synthesis of Thromboxane A2, potent agonist in platelet aggregation ...
Nur Hadiyanti +2 more
doaj +1 more source
Augmentation by resveratrol of the inhibitory effect of ethanol on platelet aggregation
Platelets, 2023 Ethanol and resveratrol have been shown to inhibit platelet aggregation. The aim of this study was to determine whether resveratrol has an additional effect on ethanol-induced inhibition of platelet aggregation.
Kazumi Ekawa +2 more
doaj +1 more source
Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A2, a stable analog of thromboxane A2. [PDF]
Proceedings of the National Academy of Sciences, 1980 Carbocyclic thromboxane A2 [2 beta (Z),3 alpha- (1E,3R*)-3-(3-hydroxy(1-octenyl)-bicyclo[3.1.1]hept-2-yl-5-heptenoic acid], a stable analog of thromboxane A2, has been tested for its physiologic properties. Carbocyclic thromboxane A2 is a potent coronary vasoconstrictor, stimulating cornonary vascular smooth muscle at concentrations as low as 29 pM. At
A M, Lefer +7 more
openaire +2 more sources